A new trading day began on Tuesday, with Takeda Pharmaceutical Co ADR (NYSE: TAK) stock price up 0.07% from the previous day of trading, before settling in for the closing price of $13.43. TAK’s price has ranged from $12.57 to $15.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 11.56% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -7.54%. With a float of $3.17 billion, this company’s outstanding shares have now reached $3.17 billion.
In an organization with 49281 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.23%, operating margin of 11.21%, and the pretax margin is 5.87%.
Takeda Pharmaceutical Co ADR (TAK) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Takeda Pharmaceutical Co ADR is 0.00%, while institutional ownership is 5.00%. The most recent insider transaction that took place on Aug 23 ’24, was worth 284,951.
Takeda Pharmaceutical Co ADR (TAK) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.67% during the next five years compared to -12.87% drop over the previous five years of trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Here are Takeda Pharmaceutical Co ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.41. Likewise, its price to free cash flow for the trailing twelve months is 7.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.43, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach 0.46 in one year’s time.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.68 million. That was inferior than the volume of 2.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 40.10%. Additionally, its Average True Range was 0.18.
During the past 100 days, Takeda Pharmaceutical Co ADR’s (TAK) raw stochastic average was set at 29.91%, which indicates a significant decrease from 59.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.54% in the past 14 days, which was higher than the 16.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.32, while its 200-day Moving Average is $13.68. However, in the short run, Takeda Pharmaceutical Co ADR’s stock first resistance to watch stands at $13.47. Second resistance stands at $13.51. The third major resistance level sits at $13.55. If the price goes on to break the first support level at $13.40, it is likely to go to the next support level at $13.36. Assuming the price breaks the second support level, the third support level stands at $13.32.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Key Stats
With a market capitalization of 42.61 billion, the company has a total of 3,181,875K Shares Outstanding. Currently, annual sales are 29,420 M while annual income is 994,060 K. The company’s previous quarter sales were 7,511 M while its latest quarter income was 156,180 K.
